Laura Duzzi1,#,*, Nora Möhn1,#, Emily Narten1, Janin Thomas1, Susann Mahjoub1, Lea Grote-Levi1, Konstantin Jendretzky1, Sandra Nay1, Felix Konen1, Jonas Wiegmann2, Gernot Beutel2, Tabea Fröhlich2, Benjamin-Alexander Bollmann3, Thomas Wirth4, Imke von Wasielewski5, Florian H. Heidel2, Ralf Gutzmer5,6, Thomas Skripuletz1,§, Philipp Ivanyi2,§, the ICOG (Immune Cooperative Oncology Group)-Investigators7
Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074095
- 22 April 2026
Abstract Objectives: Since 2011, immune checkpoint inhibitors (ICI) have transformed the treatment of various cancers. However, our understanding of the autoimmune adverse events, particularly those affecting the nervous system, remains limited. These adverse events can cause significant disability or even death, yet there are currently no established guidelines or biomarkers to aid diagnosis and treatment. With this study, we aim to gain a deeper understanding of neurological adverse events and investigate potential predictive biomarkers. Methods: Between 19 December 2019 and 21 August 2021, 150 out of 543 ICI-treated cancer patients were eligible for our prospective monocentric… More >